对于使用芬太尼尔的人来说,室外患者低剂量启动布普伦诺芬
Leslie W Suen1, Amy Y Chiang1, Benjamin L H Jones2
1Division of General Internal Medicine at San Francisco General Hospital, Department of Medicine, University of California, San Francisco, San Francisco.
JAMA network open
|January 24, 2025
概括
在使用芬太尼 (fentanyl) 的阿片类药物使用障碍 (OUD) 患者中,使用低剂量启动 (LDI) 协议启动布普伦诺芬的成功率较低. 需要进一步的研究来改善布普伦诺芬的吸收和保留.
科学领域:
- 成 药物 药物 药物 药物
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 高强度阿片类药物,如芬太尼,由于急性戒断风险,复杂化了布普伦诺芬的启动.
- 低剂量启动 (LDI) 被作为一种策略探索,但缺乏比较结果数据.
研究的目的:
- 评估使用芬太尼 (fentanyl) 的阿片类药物使用障碍 (OUD) 患者的布普伦诺芬启动两种LDI协议的门诊结果.
- 为了比较4天和7天LDI协议之间的成功率和保留率.
主要方法:
- 一项队列研究分析了来自两个诊所的126名OUD和每日芬太尼使用的成年人的数据.
- 数据包括175次使用4天或7天LDI协议启动布普伦诺芬的尝试.
- 测量结果是成功启动 (完成和补充) 和28天的保留,使用后勤回归和生存模型进行分析.
主要成果:
- 总体而言,成功的布普伦诺芬启动率为34%,在4天 (38%) 和7天 (28%) 的LDI协议之间没有显著差异.
- 28天后布普伦诺啡的保留率很低 (21%为4天,18%为7天),协议之间没有显著差异.
- 重复的LDI尝试与较低的成功率有关.
结论:
- 在使用芬太尼的OUD患者中,对布普伦诺芬的门诊LDI启动产生了低的成功率和保留率.
- 需要进行干预措施,以提高LDI的成功率,布普伦诺芬的吸收率和患者在治疗中保持时间.
相关概念视频
Drug Dependence
Medications are typically administered to achieve therapeutic effects. Some drugs can modify an individual's mood and perception, frequently resulting in various enjoyable experiences. However, this can result in drug dependency, a condition marked by continuous drug use despite potential negative consequences. Drug dependency primarily falls into two categories: psychological and physical dependence. Psychological dependence occurs when the pleasurable feelings induced by the drug...
Opioid Receptors: Overview
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Opioid Analgesics: Morphine and Other Natural Cogeners
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...


